Veronika Maria Metzler

Veronika Maria Metzler

Auto-generated profile, based on publicly available information

Veronika Maria Metzler

Department of Otorhinolaryngology and Head and Neck Surgery, Medical University of Innsbruck, Innsbruck, Austria

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 October 2015 in Oncotarget
Verified
Journal Article
Open access
PDF file
TSTeresa Bernadette Steinbichler
Teresa Bernadette Steinbichler
VMVeronika Metzler
Veronika Metzler
CPChristian Pritz
Christian Pritz
HRHerbert Riechelmann
Herbert Riechelmann
Jozsef DudasJozsef Dudas
Jozsef Dudas
Tumor-associated fibroblast-conditioned medium induces CDDP resistance in HNSCC cells

18 August 2017 in Clinical Endocrinology
Verified
Journal Article
Open access
PDF file
WAWilliam Atiomo
William Atiomo
MSMohamad Nasir Shafiee
Mohamad Nasir Shafiee
CCCaroline Chapman
Caroline Chapman
VMVeronika M. Metzler
Veronika M. Metzler
JAJad Abouzeid
Jad Abouzeid
NMNigel P Mongan
Nigel P Mongan
Summary: Objective: Women with a prior history of polycystic ovary syndrome (PCOS) have an increased risk of endometrial cancer (EC).Aim: To investigate whether the endometrium of women withPCOSpossesses gene expression changes similar to those found inEC.Design and Methods: Patients withEC,PCOSand control women unaffected by eitherPCOSorECwere recruited into a cross‐sectional study at the Nottingham University Hospital,UK. ForRNAsequencing, representative individual endometrial biopsies were obtained from women withEC,PCOSand a woman unaffected byPCOSorEC. Expression of a subset of differentially expressed genes identified byRNAsequencing, includingNAD(P)H quinone dehydrogenase 1 (NQO1), was validated by quantitative reverse transcriptasePCRvalidation (n = 76) and in the cancer genome atlasUCEC(uterine corpus endometrioid carcinoma)RNAsequencing data set (n = 381). The expression ofNQO1 was validated by immunohistochemistry inECsamples from a separate cohort (n = 91) comprised of consecutive patients who underwent hysterectomy at St Mary's Hospital, Manchester, between 2011 and 2013. A further 6 postmenopausal women with histologically normal endometrium who underwent hysterectomy for genital prolapse were also included. Informed consent and local ethics approval were obtained for the study.Results: We show for the first thatNQO1expression is significantly increased in the endometrium of women withPCOSandEC. Immunohistochemistry confirms significantly increasedNQO1 protein expression inECrelative to nonmalignant endometrial tissue (P < .0001).Conclusions: The results obtained here support a previously unrecognized molecular link betweenPCOSandECinvolvingNQO1.

20 November 2017 in Tumor Biology
Verified
Journal Article
Open access
PDF file
VMVeronika Maria Metzler
Veronika Maria Metzler
CPChristian Pritz
Christian Pritz
ARAnna Riml
Anna Riml
ARAngela Romani
Angela Romani
RTRaphaela Tuertscher
Raphaela Tuertscher
Jozsef DudasJozsef Dudas
Jozsef Dudas
Fibroblasts play a central role in tumor invasion, recurrence, and metastasis in head and neck squamous cell carcinoma. The aim of this study was to investigate the influence of tumor cell self-produced factors and paracrine fibroblast–secreted factors in comparison to indirect co-culture on cancer cell survival, growth, migration, and epithelial–mesenchymal transition using the cell lines SCC-25 and human gingival fibroblasts. Thereby, we particularly focused on the participation of the fibroblast-secreted transforming growth factor beta-1.Tumor cell self-produced factors were sufficient to ensure tumor cell survival and basic cell growth, but fibroblast-secreted paracrine factors significantly increased cell proliferation, migration, and epithelial–mesenchymal transition–related phenotype changes in tumor cells. Transforming growth factor beta-1 generated individually migrating disseminating tumor cell groups or single cells separated from the tumor cell nest, which were characterized by reduced E-cadherin expression. At the same time, transforming growth factor beta-1 inhibited tumor cell proliferation under serum-starved conditions. Neutralizing transforming growth factor beta antibody reduced the cell migration support of fibroblast-conditioned medium. Transforming growth factor beta-1 as a single factor was sufficient for generation of disseminating tumor cells from epithelial tumor cell nests, while other fibroblast paracrine factors supported tumor nest outgrowth. Different fibroblast-released factors might support tumor cell proliferation and invasion, as two separate effects.

1 August 2017 in Placenta
Verified
Journal Article
Closed access
VMVeronika M. Metzler
Veronika M. Metzler
SBSimone de Brot
Simone de Brot
RRRobert S. Robinson
Robert S. Robinson
JJJennie N. Jeyapalan
Jennie N. Jeyapalan
Emad A RakhaEmad A Rakha
Emad A Rakha
NMNigel P Mongan
Nigel P Mongan

21 September 2016 in Endocrine Abstracts
Verified
Journal Article
Closed access
VMVeronika M Metzler
Veronika M Metzler
BDBrot Simone de
Brot Simone de
JWJonathan B Whitchurch
Jonathan B Whitchurch
BRBrian D Robinson
Brian D Robinson
SBStephen Boorjian
Stephen Boorjian
NMNigel P Mongan
Nigel P Mongan
Androgen Receptor (AR) is central to prostate cancer (PCa) tumorigenesis and metastases. The genomic actions of androgens are mediated by the AR in complex with multiple chromatin modifying coregulators. We and others have identified lysine demethylases (KDMs) as important mediators of androgen signaling and increased expression of specific coregulators, including KDM1A, are implicated in PCa recurrence. There is an urgent need for new PCa treatments. While androgen deprivation therapies (ADT) impede tumor progression, castrate resistant PCa (CRPC) typically arises within ~18 months. CRPCs escape androgen dependency and are incurable. The mechanisms involved in CRPC include AR mutations/splice variants and/or alterations in AR-coregulators. However AR-coregulators, in particular ‘druggable’ enzymes including KDMs, offer alternative targets to circumvent resistance to existing ADTs. We reported that the androgen-induced microRNA-137 (miR137) acts as a suppressor of an extended network of transcriptional coregulators, including KDM1A and KDM7A, in normal prostate cells. However loss of miR137 in PCa contributes to increased expression of these coregulators. Here we report that androgen induces KDM7A expression in hormone responsive LNCaP cells. siRNA-mediated functional depletion of KDM7A expression impairs androgen induction of KLK3/PSA and the pro-angiogenesis factor VEGFA in LNCaP and its hormone-refractory derivative, LNCaP:C4-2. We examined KDM7A expression in PCa specimens and correlate expression with key clinical parameters. Collectively our data supports a role for KDM7A in androgen dependent and refractory PCa. Thus KDM7A, like KDM1A, represents a novel potential drug-target to inhibit androgen signaling in hormone dependent and refractory contexts and thereby potentially circumvent resistance to existing ADTs. Funding: We gratefully acknowledge the financial support of the BBSRC doctoral training program and the University of Nottingham. Presenting author: Veronika Metzler, Faculty of Medicine and Health Sciences, School of Veterinary Medicine and Health Sciences, University of Nottingham, UK. Email: stxvm8@nottingham.ac.uk.